SCHEMBL12648463

SCHEMBL12648463

CCN(CC)C(=O)N1CCC(c2nc(C3Cc4cccc(Cl)c4N3)c3c(N)ncnn23)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK2A2 P19784 2/20 0.38
RIPK2 O43353 1/20 0.38
RET P07949 1/20 0.38
NQO2 P16083 1/20 0.38
FECH P22830 1/20 0.38
ACVR1B P36896 1/20 0.38
TGFBR1 P36897 1/20 0.38
PIK3CA P42336 1/20 0.38
MTOR P42345 1/20 0.38
PIK3CG P48736 1/20 0.38
MAPK10 P53779 1/20 0.38
PRKDC P78527 1/20 0.38
MAP2K5 Q13163 1/20 0.38
BMPR2 Q13873 1/20 0.38
RICTOR Q6R327 1/20 0.38
RPTOR Q8N122 1/20 0.38
PIP4K2C Q8TBX8 1/20 0.38
MAPKAP1 Q9BPZ7 1/20 0.38
MLST8 Q9BVC4 1/20 0.38
NLK Q9UBE8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12648183 0.92 RAF1 (0.41) CSNK2A2RIPK2RETNQO2FECH
SCHEMBL8399556 0.83 MTOR (0.51) CSNK2A2RIPK2RETNQO2FECH
SCHEMBL13629449 0.82 MTOR (0.43) CSNK2A2RIPK2RETNQO2FECH
SCHEMBL12648416 0.82 TNK2 (0.53) CSNK2A2RIPK2RETNQO2FECH
SCHEMBL13629023 0.81 IGF1R (0.43) CSNK2A2RIPK2RETNQO2FECH
SCHEMBL10240939 0.80 TNK2 (0.40) CSNK2A2RIPK2RETNQO2FECH
SCHEMBL12648245 0.79 CSNK2A2 (0.46) CSNK2A2RIPK2RETNQO2FECH
SCHEMBL6941177 0.78 MTOR (0.59) CSNK2A2RIPK2RETNQO2FECH
SCHEMBL8402334 0.77 MTOR (0.41) CSNK2A2RIPK2RETNQO2FECH
SCHEMBL12648432 0.76 MTOR (0.50) CSNK2A2RIPK2RETNQO2FECH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7943767-B2 Fused bicyclic mTOR inhibitors OSI PHARMACEUTICALS, INC. (US) 2011-05-17 US disclosed
US-20100099679-A1 FUSED BICYCLIC mTOR INHIBITORS OSI PHARMACEUTICALS, INC. 2010-04-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099679-A1 FUSED BICYCLIC mTOR INHIBITORS MTOR, RICTOR, MAPKAP1 CSNK2A2 871/4885RIPK2 1316/4885RET 744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.